Skip to content

EPS (Basic) at other companies

Gilead Sciences logo
Gilead SciencesGILD
$1.63+53.8%
Arrowhead Research logo
Arrowhead ResearchARWR
-$0.93-133%
Alkermes logo
AlkermesALKS
-$0.40-386%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$0.56+39.8%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
LQD
Liquidia CorporationLQDA

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s EPS (basic)?
Mirum Pharmaceuticals, Inc. (MIRM) reported EPS (basic) of -$13.43 in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s EPS (basic) changed year-over-year?
Mirum Pharmaceuticals, Inc.'s EPS (basic) decreased by 4376.7% year-over-year, from -$0.30 to -$13.43.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s EPS (basic)?
Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s EPS (basic) has grown at a -50.7% compound annual growth rate (CAGR), from -$4.01 to -$0.48.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.